Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor
Authors:
- Ton LismanTLTon Lisman
- Jelle AdelmeijerJAJelle Adelmeijer
- H Karel NieuwenhuisHNH Karel Nieuwenhuis
- Philip G de GrootPGPhilip G de Groot
- 1 September 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 14 (6) , 557-562
Abstract
Tissue factor-induced coagulation leads to the generation of a small amount of thrombin, resulting in the formation of a fibrin clot. After clot formation, thrombin generation continues resulting in the activation of thrombin activatable fibrinolysis inhibitor, leading to downregulation of fibrinolysis. In this study, the effect of anticoagulant drugs targeting different steps in the coagulation cascade on clot formation and subsequent breakdown was investigated using a plasma-based clot lysis assay. All drugs tested significantly delayed clot formation; only those drugs targeting activated factor X (FXa) (tissue factor pathway inhibitor, fondaparinux, and low molecular weight heparin) accelerated fibrinolysis. Anticoagulant drugs targeting tissue factor (active site-inactivated recombinant activated factor VII) or thrombin (hirudin and d-phenylalanyl-l-prolyl-l-arginyl chloromethyl ketone) did not affect clot lysis time. In accordance with these findings, it was shown that total thrombin generation, as quantified by the endogenous thrombin potential, was only affected by anticoagulant drugs targeting FXa when all drugs were used in a concentration resulting in doubling of clotting time. Induction of hyperfibrinolysis by anticoagulant drugs directed against FXa might be beneficial as increased clot breakdown might facilitate thrombolysis or prevent re-occlusion. On the other hand, the induction of hyperfibrinolysis by these compounds might increase the risk of bleeding complications.Keywords
This publication has 32 references indexed in Scilit:
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' dataThe Lancet, 2002
- Fondaparinux SodiumDrugs, 2002
- Anticoagulant Factor Concentrates in Disseminated Intravascular Coagulation: Rationale for Use and Clinical ExperienceSeminars in Thrombosis and Hemostasis, 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryNew England Journal of Medicine, 2001
- Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)Thrombosis Research, 2001
- Hemorrhagic Complications of Anticoagulant TreatmentChest, 2001
- Active site-blocked activated factor VII as an effective antithrombotic agent: mechanism of actionBlood Coagulation & Fibrinolysis, 2000
- Tissue Factor Pathway Inhibitor: Potential Therapeutic ApplicationsThrombosis and Haemostasis, 1997
- Hirudin and hirudin analogues as new anticoagulant agentsCurrent Opinion in Hematology, 1995
- Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboonsBlood, 1993